NCT04220229View on ClinicalTrials.gov

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

April 5, 2024

Study Completion Date

October 31, 2024

Conditions
Sarcoma of the ExtremityStage I Soft Tissue Sarcoma of the Trunk and ExtremitiesStage IA Soft Tissue Sarcoma of the Trunk and ExtremitiesStage IB Soft Tissue Sarcoma of the Trunk and ExtremitiesStage II Soft Tissue Sarcoma of the Trunk and Extremities
Interventions
DRUG

Cabozantinib S-malate

Given PO

RADIATION

Radiation Therapy

Undergo standard of care radiation therapy

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

University of Washington

OTHER

NCT04220229 - Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | Biotech Hunter | Biotech Hunter